Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models

11 Aug 2022

Abstract excerpt

BACKGROUND: The majority of high-risk neuroblastomas harbor telomerase activity, and telomerase-interacting compounds, such as 6-thio-2'-deoxyguanosine (6-thio-dG), have been found to impair the growth of telomerase-positive neuroblastoma cell lines. It has remained unclear, however, how such drugs can be combined with other compounds used in current treatment concepts for neuroblastoma patients. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to Cancer therapeutics and mechanisms
Share to Telomeres, Telomerase, and Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35953764
DOI: 10.1007/s13402-022-00702-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma modelsPMID 35953764Read ↗

Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in NeuroblastomaSemantic proximity Read ↗

Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastomaSemantic proximity Read ↗

In perspective: An update on telomere targeting in cancerSemantic proximity Read ↗

Telomerase-based Cancer Therapeutics: A Review on their Clinical TrialsSemantic proximity Read ↗

A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cellsSemantic proximity Read ↗

Telomerase-Targeted Cancer ImmunotherapySemantic proximity Read ↗

Telomerase Inhibition in Cancer Therapeutics: Molecular-Based ApproachesSemantic proximity Read ↗

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.Semantic proximity Read ↗

Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in NeuroblastomaSemantic proximity Read ↗

Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-DeoxyguanosineSemantic proximity Read ↗

Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain TumorsSemantic proximity Read ↗

Mechanism-based combination telomerase inhibition therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.